Loading clinical trials...

FIND CAN Trial: "CF-172" | Clinical Trials | Clareo Health

COMPLETEDNA

FIND CAN Trial: "CF-172"

Feasibility of the CARTOFINDER™ 4D LAT Algorithm to Identify Ablation Target in Subjects With Atrial Fibrillation (FIND CAN Trial: "CF-172")

NCT03033641•Biosense Webster, Inc.

View on ClinicalTrials.gov

Summary

The purpose of this feasibility study is to further explore characteristics of ablation targets identified by CARTOFINDER 4D LAT Algorithm in subjects with persistent atrial fibrillation and to assess the acute outcome of CARTOFINDER Guided Ablation in terms of the termination of atrial fibrillation to either Normal Sinus Rhythm or Atrial Tachycardia.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Age \> 18 years.
•2. Patients who have signed the Patient Informed Consent Form (ICF)
•3. Scheduled to undergo a clinically-indicated catheter ablation procedure for treatment of persistent atrial fibrillation (defined as continuous atrial fibrillation that is sustained beyond seven consecutive days).
•3.1. Drug-refractory atrial fibrillation. (failed 1 or more class I or III antiarrhythmic drugs) and demonstrating Persistent AF (requiring drugs or electrical shock to terminate)
•4. Able and willing to comply with all pre-, post-, and follow-up testing and requirements (e.g. patients not confined by a court ruling)

Exclusion Criteria

•1. Paroxysmal Atrial Fibrillation
•2. Continuous AF \> 12 months (1 Year) (Longstanding Persistent AF) 2.1. Subjects previously diagnosed as Long Standing Persistent (LSP) but have demonstrated the ability to maintain Normal Sinus Rhythm for \>30 days after cardioversion and have not been in AF greater than 1 year at the time of the procedure remain eligible for inclusion.
•3. Previous ablation procedure for AF (previous ablation for the treatment of Flutter is acceptable)
•4. Patients with a left atrial size \>55 mm (echocardiography, parasternal long axis view).
•5. Inability to restore sinus rhythm for 30 seconds or longer in the opinion of the investigator.
•6. Significant congenital anomaly or medical problem that in the opinion of the investigator would preclude enrollment in this study.
•7. Atrial arrhythmia patients with structural atrial disease such as a prior history of atriotomy from prior atrial surgery, presence of an atrial septal defect, and/or presence of an atrial septal closure patch.
•8. History of or current blood clotting or bleeding abnormalities, contraindication to systemic anticoagulation (i.e., heparin, warfarin, dabigatran, or a direct thrombin inhibitor), significant pulmonary disease, unstable angina, uncontrolled heart failure, acute illness or systemic infection, or any other disease or malfunction that would preclude treatment in the opinion of the investigator.
•9. Enrollment in a study evaluating another device or drug.
•10. A complex arrhythmia secondary to electrolyte imbalance, thyroid disease, or reversible or non-cardiac cause.
+8 more criteria

Key Dates

Start Date

December 5, 2016

Primary Completion Date

May 4, 2017

Completion Date

August 30, 2017

Last Updated

February 3, 2025

Enrollment

ESTIMATED participants

Conditions

Persistent Atrial Fibrillation

Interventions

Ablation procedure

DEVICE

Medtronic Terminate AF Study

NCT03546374

Persistent Atrial FibrillationLongstanding Persistent Atrial Fibrillation

View study

RECRUITINGNA

FIH Study of PFLotus in Persistent Atrial Fibrillation

NCT07301190

Persistent Atrial Fibrillation

View study

RECRUITINGNA

Hybrid Ablation of Atrial Fibrillation in Heart Failure

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 3, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

FIND CAN Trial: "CF-172"

Inclusion Criteria

Exclusion Criteria

Medtronic Terminate AF Study

FIH Study of PFLotus in Persistent Atrial Fibrillation

Hybrid Ablation of Atrial Fibrillation in Heart Failure

Pragmatic Evaluation of a Pentaspline Pulsed Field Ablation System to Treat Atrial Fibrillation and Related Arrhythmias

VOLT CE Mark Study

ARIADNE Clinical Trial